Array BioPharma and Genentech Expand Oncology Collaboration
Array BioPharma announced an expansion of a collaboration agreement with Genentech, Inc. to develop small molecule drugs against an additional protein target in the field of oncology.
The original collaboration, which began in January 2004, was formed to advance two of Array's proprietary oncology programs into clinical development. Under the expanded agreement, Array will receive additional research funding, as well as research and development milestone payments and product royalties based on the success of the new program.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Specialist Business Unit of the University of Nottingham Spins-Out to Form New R&D Oncology Company
Sanofi to acquire Bioverativ for $11.6 billion
Crucell Announces Start of Universal RSV Vaccine Program
Compugen Announces Preeclampsia Biomarker Collaboration - Collaboration Based on Compugen Discovered VEGF Receptor Splice Variant
Protein found to regulate spread of pancreatic cancer cells
Merck Meets all Financial Targets and Makes Significant Strategic Progress
Wyeth Extends Agreement with Affymetrix to 15 Years
Golden LEAF Launches State's Biotechnology Initiative With $60 Million Commitment
